GlassScriptPhysician profile
Jay R Heckert
NPI 1922661222
$2,278.12
in general payments reported to CMS, 2019-2025
20 companies · $780 in 2025
The $780 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.40 · 2021: $24.29 · 2022: $312 · 2023: $515 · 2024: $619 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,514 · Education: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,514.38 |
| Education | $398.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $726.60 | 2021-2025 | Impella |
| Medtronic, INC. | $654.28 | 2022-2023 | |
| Amgen INC. | $180.90 | 2025 | Repatha |
| Boston Scientific Corporation | $144.44 | 2024 | Watchman Flx |
| Abbott Laboratories | $133.49 | 2025 | Triclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.45 | 2019-2025 | Jardiance |
| Impulse Dynamics (USA) INC. | $43.85 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $41.04 | 2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $34.07 | 2025 | |
| Esperion Therapeutics, INC. | $32.46 | 2023-2025 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $29.66 | 2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.78 | 2024-2025 | Lifevest |
| Lantheus Medical Imaging, INC. | $26.04 | 2023 | |
| Biosense Webster, INC. | $25.43 | 2023 | Carto 3, Soundstar |
| Bayer Healthcare Pharmaceuticals INC. | $25.37 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $21.95 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $19.95 | 2023 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $16.03 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $13.63 | 2025 | |
| Lilly USA, LLC | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Heckert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.